Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSuzanne Trudel(Princess Margaret Cancer Centre), A. Keith Stewart(Princess Margaret Hospital)BloodMarch 2, 200710.1182/blood-2006-10-047951Cited by 217SaveCiteExport RISWatch citationsRelated PapersCevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study|Blood|2021|161Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression|Nature Communications|2021|30